Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Tri Locum Partners LP

Tri Locum Partners LP raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 212.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 209,984 shares of the company's stock after acquiring an additional 142,727 shares during the quarter. Novo Nordisk A/S makes up 3.7% of Tri Locum Partners LP's investment portfolio, making the stock its 13th biggest holding. Tri Locum Partners LP's holdings in Novo Nordisk A/S were worth $18,063,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. GQG Partners LLC grew its position in shares of Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $404,910,000. Loomis Sayles & Co. L P grew its position in shares of Novo Nordisk A/S by 34.2% during the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after acquiring an additional 2,947,771 shares during the last quarter. Clearbridge Investments LLC grew its position in shares of Novo Nordisk A/S by 59.8% during the fourth quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock worth $368,451,000 after acquiring an additional 1,602,549 shares during the last quarter. Finally, Sustainable Growth Advisers LP grew its position in shares of Novo Nordisk A/S by 23.6% during the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock worth $459,416,000 after acquiring an additional 1,021,498 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on NVO shares. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded down $0.78 during midday trading on Thursday, reaching $65.67. The company's stock had a trading volume of 12,052,624 shares, compared to its average volume of 8,987,258. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock's 50 day simple moving average is $72.40 and its 200 day simple moving average is $88.69. The firm has a market capitalization of $294.68 billion, a PE ratio of 19.96, a P/E/G ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. The ex-dividend date was Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's payout ratio is 49.54%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.